%0 Journal Article
%A Goldschmidt, Hartmut
%A Lokhorst, H. M.
%A Mai, E. K.
%A van der Holt, B.
%A Blau, I. W.
%A Zweegman, S.
%A Weisel, K. C.
%A Vellenga, E.
%A Pfreundschuh, M.
%A Kersten, M. J.
%A Scheid, C.
%A Croockewit, S.
%A Raymakers, R.
%A Hose, D.
%A Potamianou, A.
%A Jauch, A.
%A Hillengass, J.
%A Stevens-Kroef, M.
%A Raab, M. S.
%A Broijl, A.
%A Lindemann, H. W.
%A Bos, G. M. J.
%A Brossart, P.
%A van Marwijk Kooy, M.
%A Ypma, P.
%A Duehrsen, U.
%A Schaafsma, R. M.
%A Bertsch, U.
%A Hielscher, Thomas
%A Jarari, Le
%A Salwender, H. J.
%A Sonneveld, P.
%T Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.
%J Leukemia
%V 32
%N 2
%@ 1476-5551
%C Basingstoke
%I Nature Publ. Group
%M DKFZ-2018-00163
%P 383 - 390
%D 2018
%X The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR)=0.76, 95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:28761118
%R 10.1038/leu.2017.211
%U https://inrepo02.dkfz.de/record/132475